ANIP rare disease and generics growth drives revenues past $1B
The company says rare-disease products such as Cortrophin Gel and its generics business have driven revenue over $1B, with an outlook supported by durable IP and capital allocation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.